Why Ozempic Causes Hypoglycemia When Combined With Insulin or Sulfonylureas

What does the Ozempic label say about the combination?

Ozempic's hypoglycemia warning is written for combination use. Section 5.5 of the label states that patients receiving Ozempic with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia, including severe hypoglycemia, and that the risk may be lowered by a reduction in the dose of the sulfonylurea or insulin [1].

The drug interactions section gives the label's reasoning in one sentence: Ozempic stimulates insulin release in the presence of elevated blood glucose concentrations. It then advises considering a lower dose of the insulin secretagogue or insulin when Ozempic is started, to reduce the risk of hypoglycemia. These sections give no percentage for the reduction [1].

Does Ozempic alone cause low blood sugar?

In the 30-week monotherapy trial in adults with type 2 diabetes (129 on placebo, 127 on Ozempic 0.5 mg, 130 on 1 mg), severe hypoglycemia, meaning an episode requiring another person's assistance, occurred in 0% of all three groups. Documented symptomatic hypoglycemia at a glucose threshold of 70 mg/dL or below occurred in 0% on placebo, 1.6% on 0.5 mg and 3.8% on 1 mg [1].

So low readings did occur on semaglutide alone, at low rates, and that trial recorded no severe episodes.

What the insulin trial showed

The label's 30-week trial of Ozempic added to basal insulin, with or without metformin, enrolled 132 on placebo, 132 on 0.5 mg and 131 on 1 mg. Documented symptomatic hypoglycemia at 70 mg/dL or below occurred in 15.2% on placebo, 16.7% on 0.5 mg and 29.8% on 1 mg. Severe hypoglycemia, or symptomatic hypoglycemia confirmed at 56 mg/dL or below, occurred in 5.3%, 8.3% and 10.7% respectively, and severe hypoglycemia alone in 0%, 0% and 1.5% [1].

Sulfonylureas and Ozempic

The label's hypoglycemia warning names insulin secretagogues such as sulfonylureas alongside insulin. The label notes that hypoglycemia was more frequent when Ozempic was used in combination with a sulfonylurea [1].

What else the label says for people on insulin

The label tells prescribers to inform patients taking these medicines about the risk of hypoglycemia and to educate them on its signs and symptoms [1]. For people who inject insulin, it directs that Ozempic and insulin be given as separate injections and never mixed. Injecting both in the same body region is acceptable, but not at adjacent spots [1].

What semaglutide does to insulin, glucagon and gastric emptying

A randomized crossover trial of 30 adults with obesity compared semaglutide, dose-escalated to 1 mg weekly, with placebo over two 12-week periods. Semaglutide lowered fasting glucose and glucagon and raised fasting insulin compared with placebo (estimated treatment ratios 0.95, 0.86 and 1.45) [2]. It delayed first-hour gastric emptying after a standardized meal (AUC ratio 0.73, 95% CI 0.61 to 0.87), while emptying measured over 5 hours was not statistically different from placebo [2]. The study was not a hypoglycemia trial.